Mechanism of Action
Receptor Biology (Ongoing Research)
The original claim that obestatin binds GPR39 was not reproducible by independent laboratories, creating uncertainty about the primary receptor. Subsequent research suggested obestatin may interact with the GLP-1 receptor at pharmacological concentrations, with glucagon receptor, or with currently unidentified receptors. Some effects may involve intracellular signaling pathways activated independently of a classical GPCR. Resolving the obestatin receptor remains an active area of investigation.
Cellular Effects
Regardless of receptor uncertainty, cell culture studies consistently show obestatin activates Akt/PKB and ERK1/2 survival pathways in pancreatic beta cells, cardiomyocytes, and skeletal muscle cells. These pro-survival signals reduce apoptosis in ischemic and metabolic stress conditions. Obestatin also promotes pancreatic beta cell proliferation and insulin secretion in some studies, supporting a role in glucose homeostasis.
Research Summary
Pancreatic Beta Cell Protection
AnimalObestatin promotes beta cell survival, proliferation, and insulin secretion in rodent models of diabetes. In streptozotocin-diabetic mice, obestatin partially restored beta cell mass and improved glycemic control. These findings suggest obestatin may be relevant to beta cell preservation strategies in type 1 and type 2 diabetes.
Cardioprotection
AnimalObestatin reduced infarct size and improved cardiac function when administered before or during ischemia-reperfusion in rat hearts. The mechanism involves PI3K/Akt activation and reduced apoptosis of cardiomyocytes during reperfusion. These effects parallel the cardioprotective properties of several other GI peptides.
Muscle Regeneration
AnimalObestatin promotes satellite cell proliferation and skeletal muscle regeneration after injury. Systemic obestatin improved muscle function recovery in models of muscular dystrophy and exercise-induced injury. These findings represent one of the more reproducible obestatin effects and are potentially relevant to sarcopenia and muscle wasting conditions.
Calculate your Obestatin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Beta cell / metabolic research | 8-100 nmol/kg | Daily x 2-4 weeks | Subcutaneous |
| Muscle regeneration | 50-100 nmol/kg | Daily x 1-2 weeks | Subcutaneous |
Obestatin research is complicated by species differences and the unresolved receptor question. Results vary considerably across studies and laboratories.
Interactions
Safety Profile
Animal studies have not identified significant toxicity at research doses. The receptor uncertainty limits confident prediction of off-target effects. Obestatin's derivation from the same gene as ghrelin suggests endogenous physiological roles, and circulating obestatin is detectable in human plasma. No human interventional safety data exists.
References
- [1]Zhang JV, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science. 2005;310(5750):996-999.
- [2]Granata R, et al. Obestatin promotes survival of pancreatic beta-cells and human islets and induces expression of genes involved in the regulation of beta-cell mass and function. Diabetes. 2008.
- [3]Delhanty PJ, et al. The acylated (AG) to unacylated ghrelin (UAG) ratio and obestatin: evidence for independent effects in health and disease. Peptides. 2011.